Ken Griffin Talaris Therapeutics, Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.68 - $3.22 $266,048 - $319,655	-99,272 Reduced 46.44%	114,482 $321,000
Q2 2023 Aug 14, 2023	SELL	$1.78 - $3.2 $1.48 Million - $2.66 Million	-831,372 Reduced 79.55%	213,754 $649,000
Q1 2023 May 15, 2023	SELL	$1.09 - $2.09 $2.7 Million - $5.18 Million	-2,477,012 Reduced 70.33%	1,045,126 $1.96 Million
Q4 2022 Feb 14, 2023	BUY	$0.94 - $1.64 $807,997 - $1.41 Million	859,572 Added 32.28%	3,522,138 $3.59 Million
Q3 2022 Nov 14, 2022	SELL	$2.3 - $5.03 $22,788 - $49,837	-9,908 Reduced 0.37%	2,662,566 $7 Million

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.